SNDX

Syndax Pharmaceuticals, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.22
52-Week Range: $12.99 – $25.59
Market Cap: $1.56B
P/E (TTM): —
EPS (TTM): -2.52
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 104.14
PEG Ratio: —
Return on Equity: -255.93%
Return on Assets: -18.67%
Gross Margin: -8.01%
Operating Margin: -54.95%
Profit Margin: -87.52%
Current Ratio: 6.77
Debt/Equity: 39.03
Total Debt: $589.38M
Free Cash Flow: $-150.08M
Revenue Growth: 91.80%
Earnings Growth: —
Enterprise Value: $1.61B

SNDX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$23.68M	$172.35M
Cost of Revenue	$0.00	$0.00	$826.00K	$6.97M
Gross Profit	$0.00	$0.00	$22.85M	$165.38M
Research & Development	$118.50M	$163.03M	$241.65M	$258.78M
Selling, General & Admin	$33.26M	$66.92M	$120.88M	$179.68M
Operating Expenses	$151.76M	$229.95M	$362.53M	$438.47M
Operating Income	-$151.76M	-$229.95M	-$339.67M	-$273.08M
EBITDA	-$146.17M	-$209.14M	-$313.82M	-$251.63M
Pretax Income	-$149.34M	-$209.36M	-$318.76M	-$285.42M
Net Income	-$149.34M	-$209.36M	-$318.76M	-$285.42M
Diluted EPS	-2.46	-2.98	-3.72	-3.29
Diluted Shares	60.76M	70.37M	85.62M	86.63M

SNDX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$74.36M	$295.39M	$154.08M	$134.93M
Receivables	$4.06M	$1.23M	$13.87M	$70.29M
Inventory	—	$0.00	$366.00K	$32.75M
Current Assets	$489.79M	$580.88M	$603.06M	$528.08M
Total Assets	$497.24M	$612.88M	$724.82M	$529.71M
Current Liabilities	$29.07M	$58.10M	$103.55M	$120.12M
Long-Term Debt	—	—	$331.56M	$343.91M
Total Debt	$1.16M	$1.64M	$345.74M	$345.43M
Total Liabilities	$29.79M	$58.68M	$436.69M	$465.08M
Retained Earnings	-$693.04M	-$902.40M	-$1.22B	-$1.51B
Shareholders' Equity	$467.45M	$554.20M	$288.12M	$64.63M
Working Capital	$460.72M	$522.78M	$499.51M	$407.96M
Net Debt	—	—	$189.60M	$208.98M

SNDX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$133.68M	-$160.60M	-$274.90M	-$322.98M
Capital Expenditure	—	—	—	-$187.00K
Free Cash Flow	-$133.68M	-$160.60M	-$274.90M	-$323.17M
Depreciation & Amortisation	$33.00K	$12.00K	$8.00K	$6.00K
Stock-Based Compensation	$16.02M	$30.95M	$43.03M	$47.50M
Investing Cash Flow	-$186.19M	$117.61M	-$219.78M	$290.04M
Financing Cash Flow	$172.25M	$264.13M	$353.37M	$13.68M
Net Change in Cash	-$147.61M	$221.14M	-$141.31M	-$19.27M

SNDX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$20.04M	$37.96M	$45.87M	$68.73M	$64.86M	$72.79M
Cost of Revenue	$885.00K	$1.28M	$2.10M	$2.71M	$2.63M	$3.21M
Gross Profit	$19.16M	$36.68M	$43.77M	$66.02M	$62.23M	$69.58M
Research & Development	$61.64M	$62.23M	$56.28M	$78.64M	$58.84M	$68.04M
Selling, General & Admin	$41.03M	$43.80M	$44.92M	$49.93M	$37.59M	$41.54M
Operating Expenses	$102.91M	$106.03M	$101.20M	$128.57M	$96.43M	$109.58M
Operating Income	-$83.76M	-$69.35M	-$57.43M	-$62.55M	-$34.20M	-$39.99M
EBITDA	-$76.80M	-$63.99M	-$52.43M	-$58.42M	-$30.82M	-$36.68M
Pretax Income	-$84.85M	-$71.85M	-$60.72M	-$68.01M	-$42.67M	-$49.36M
Net Income	-$84.85M	-$71.85M	-$60.72M	-$68.01M	-$42.67M	-$49.36M
Diluted EPS	-0.98	-0.83	-0.70	-0.78	-0.48	-0.55
Diluted Shares	86.17M	86.34M	86.62M	87.36M	88.26M	88.99M

SNDX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$153.99M	$108.64M	$116.81M	$134.93M	$130.89M	$336.48M
Receivables	$21.48M	$37.42M	$43.06M	$70.29M	$60.69M	$72.78M
Inventory	$4.66M	$17.70M	$25.00M	$32.75M	$34.95M	$33.16M
Current Assets	$548.75M	$531.68M	$529.83M	$528.08M	$471.18M	$675.04M
Total Assets	$640.71M	$596.15M	$551.79M	$529.71M	$472.67M	$703.65M
Current Liabilities	$94.55M	$112.99M	$114.19M	$120.12M	$86.17M	$99.68M
Long-Term Debt	—	—	—	$343.91M	$343.96M	$588.12M
Total Debt	$1.84M	$1.68M	$1.52M	$345.43M	$345.36M	$589.38M
Total Liabilities	$425.65M	$438.73M	$436.36M	$465.08M	$431.05M	$688.55M
Retained Earnings	-$1.31B	-$1.38B	-$1.44B	-$1.51B	-$1.55B	-$1.60B
Shareholders' Equity	$215.06M	$157.42M	$115.43M	$64.63M	$41.62M	$15.10M
Working Capital	$454.20M	$418.69M	$415.64M	$407.96M	$385.00M	$575.36M
Net Debt	—	—	—	$208.98M	$213.07M	$251.64M

SNDX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$95.16M	-$87.80M	-$70.53M	-$69.49M	-$50.34M	-$30.27M
Capital Expenditure	—	—	—	-$56.00K	—	—
Free Cash Flow	-$95.16M	-$87.80M	-$70.67M	-$69.54M	-$50.34M	-$30.31M
Depreciation & Amortisation	$0.00	$0.00	$3.00K	$3.00K	$4.00K	$5.00K
Stock-Based Compensation	$10.38M	$13.79M	$12.08M	$11.25M	$12.05M	$14.01M
Investing Cash Flow	$94.14M	$41.89M	$72.43M	$81.58M	$38.39M	-$16.91M
Financing Cash Flow	$930.00K	$551.00K	$6.28M	$5.92M	$7.92M	$252.77M
Net Change in Cash	-$90.00K	-$45.36M	$8.17M	$18.01M	-$4.04M	$205.58M

Market Snapshot

About

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for cancer patients. The company focuses on entinostat, an oral HDAC inhibitor, and other epigenetic modulators in combination with immunotherapies and targeted agents. Syndax is advancing multiple clinical programs targeting both hematologic malignancies and solid tumors.